Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children’s Oncology Group


Disclosures: This research was supported by NCTN Operations Center Grant (U10CA180886) and NCTN Statistics & Data Center Grant (U10CA180899). Dr. Michael Loken is an employee of Heamatologics, Inc which performed the MRD based flow cytometry assays used in this clinical trial.

Contributions: Richard Aplenc, MD PhD: Designed research, performed research, analyzed and interpreted data, wrote the manuscript; Soheil Meshinchi, MD, PhD: Designed research, performed research, analyzed and interpreted data, wrote the manuscript; Lillian Sung, MD, PhD: Designed research, performed research, analyzed and interpreted data, wrote the manuscript; Todd Alonzo, PhD: Designed research, performed research, performed statistical analysis, wrote the manuscript; John Choi, MD, PhD: Performed research, collected data, analyzed and interpreted data; Brian Fisher, DO, MPH, MSCEE: Performed research, collected, analyzed and interpreted data; Robert Gerbing, MA: Performed research, performed statistical analysis; Betsy Hirsch, PhD: Performed research, collected data, analyzed and interpreted data; Terzah Horton, MD, PhD: Performed research, collected data, analyzed and interpreted data; Samir Khawash, MD: Performed research, collected data, analyzed and interpreted data; John Levine, MD: Performed research, collected data, analyzed and interpreted data; Michael Loken, PhD: Performed research, collected data, analyzed and interpreted data; Jessica Pollard, MD: Performed research, collected data, analyzed and interpreted data; Susan Raimondi, E PhD: Performed research, collected data, analyzed and interpreted data; Andrew Kolb, MD: Analyzed and interpreted data, wrote the manuscript; Alan Gamis, MD: Designed research, performed research, analyzed and interpreted data, wrote the manuscript.